Medical Oncology

, Volume 29, Issue 3, pp 1879–1885 | Cite as

NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma

  • Shi-peng Song
  • Sheng-bin Zhang
  • Rui Liu
  • Li Yao
  • Yu-qin Hao
  • Ming-mei Liao
  • Yang-de Zhang
  • Zhe-hai Li
Original Paper


Recent studies have demonstrated that N-Myc downstream-regulated gene 2 (NDRG2) may reduce the metastatic potential of breast cancer and hepatocellular carcinoma cells by regulating the expression of CD24, which is expressed in a large variety of solid tumors. The aim of this study was to clarify the clinical value of NDRG2 and CD24 expression in primary gallbladder carcinoma (GBC). One hundred and thirty GBC tissues were evaluated by immunohistochemistry for NDRG2 and CD24 expression. The associations of NDRG2 and CD24 expression with the clinicopathological characteristics and the overall survival of patients with GBC were analyzed. NDRG2 and CD24 were positively expressed in 49/130 (37.69%) and 107/130 (82.31%) of GBC tissues, respectively. In addition, the tumors with the down-regulation of NDRG2 and the up-regulation of CD24 more frequently had lymph node metastasis and lymphovascular invasion. Moreover, the tumors with the down-regulation of NDRG2 and the up-regulation of CD24 tended to show deeper invasion depth and higher TNM stage. There was a negative correlation between NDRG2 expression and CD24 expression in GBC tissues (r = −0.86, P < 0.001). The patients with NDRG2 negative expression correlated with poor prognosis of GBC (P = 0.01), as opposed to CD24 (P = 0.01). The survival rate of the patients with NDRG2−/CD24+ expression was the lowest (P < 0.001), and conjoined expression of NDRG2−/CD24+ was an independent prognostic indicator of GBC (P = 0.003). Our data suggest that NDRG2 down-regulation or CD24 up-regulation is an important feature of GBC. A combined detection of NDRG2/CD24 co-expression may benefit us in prediction of the prognosis in GBC.


NDRG2 CD24 Immunohistochemistry Primary gallbladder carcinoma Prognosis 


Conflict of interest



  1. 1.
    Shimizu H, Kimura F, Yoshidome H, et al. Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification. Jpn Hepatobiliary Pancreat Surg. 2007;14:358–65.CrossRefGoogle Scholar
  2. 2.
    Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res. 2004;10:3131–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Misra S, Chaturvedi A, Misra NC, et al. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167–76.PubMedCrossRefGoogle Scholar
  4. 4.
    Batmunkh E, Shimada M, Morine Y, et al. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma. Int J Clin Oncol. 2010;15:59–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Deng Y, Yao L, Chau L, et al. N-Myc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106:342–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim YJ, Yoon SY, Kim JT, et al. NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis. 2009;30:598–605.PubMedCrossRefGoogle Scholar
  7. 7.
    Piepoli A, Cotugno R, Merla G, et al. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med Genomics. 2009;2:11.PubMedCrossRefGoogle Scholar
  8. 8.
    Kim A, Kim MJ, Yang Y, et al. Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis. 2009;30:927–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Riener MO, Vogetseder A, Pestalozzi BC, et al. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract. Hum Pathol. 2010;41:1558–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Yin BB, Wu SJ, Zong HJ, et al. Preliminary screening and identification of stem cell-like sphere clones in a gallbladder cancer cell line GBC-SD. J Zhejiang Univ Sci B. 2011;12:256–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Choi YL, Lee SH, Kwon GY, et al. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med. 2007;131:275–81.PubMedGoogle Scholar
  12. 12.
    Senner V, Sturm A, Baur I, et al. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol. 1999;58:795–802.PubMedCrossRefGoogle Scholar
  13. 13.
    Keeratichamroen S, Leelawat K, Thongtawee T, et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol. 2011;39:873–81.PubMedGoogle Scholar
  14. 14.
    Diaz-Gallo LM, Medrano LM, Gómez-García M, et al. Analysis of the influence of two CD24 genetic variants in Crohn’s disease and ulcerative colitis. Hum Immunol. 2011;72:969–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Overdevest JB, Thomas S, Kristiansen G, et al. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011;71:3802–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 2005;201:479–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Liu B, Zhang Y, Liao M, et al. Clinicopathologic and prognostic significance of CD24 in gallbladder carcinoma. Pathol Oncol Res. 2011;17:45–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Zheng J, Liu Q, Li Y, et al. NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells. Asian Pac J Cancer Prev. 2010;11:1817–21.PubMedGoogle Scholar
  19. 19.
    Zheng J, Li Y, Yang J, et al. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression. BMC Cancer. 2011;251:1–9.Google Scholar
  20. 20.
    Hamilton SR, Alatonen LA. World Health Organization classification of tumours. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2004.Google Scholar
  21. 21.
    Greene FL, Page DL, Fleming ID. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.Google Scholar
  22. 22.
    Ma J, Jin H, Wang H, et al. Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull. 2008;31:1316–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhao H, Zhang J, Lu J, et al. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer. 2008;8:303.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Shi-peng Song
    • 1
  • Sheng-bin Zhang
    • 1
  • Rui Liu
    • 1
  • Li Yao
    • 2
  • Yu-qin Hao
    • 3
  • Ming-mei Liao
    • 4
  • Yang-de Zhang
    • 4
  • Zhe-hai Li
    • 5
  1. 1.Department of Genery SurgeryThe Third Affiliated Hospital of Inner Mongolia Medical College, Baogang Hospital of Inner MongoliaKun District, BaotouChina
  2. 2.Department of Genery SurgeryChina-Japan Friendship HospitalChaoyang District, BeijingChina
  3. 3.Department of DermatologyThe Third Affiliated Hospital of Inner Mongolia Medical College, Baogang Hospital of Inner MongoliaKun District, BaotouChina
  4. 4.National Hepatobiliary and Enteric Surgery Research Center of Ministry of HealthCentral South UniversityChangshaChina
  5. 5.Department of OrthopedicsThe Third Affiliated Hospital of Inner Mongolia Medical College, Baogang Hospital of Inner MongoliaKun District, BaotouChina

Personalised recommendations